Greenberg Traurig has advised ALS Limited (ALS) on the acquisition of a 49 percent equity investment in Nuvisan Group (Nuvisan). Going forward, Nuvisan will function as a center of excellence for innovation and technology development for ALS' entire life sciences network. The acquisition, which includes other subsidiaries in Germany and France, marks ALS' entry into the German market. The deal is subject to foreign trade approvals in Germany and France. The purchase price for the 49 percent stake is approximately 145 million Euros. In addition, ALS has been granted an option, subject to certain conditions, to acquire the additional 51 percent.
ALS is a global provider of laboratory testing, inspection and certification services based in Brisbane, Australia. The company operates testing centers worldwide and provides services particularly to the pharmaceutical and healthcare industries.
Nuvisan operates internationally both as an independent contract research organization, for example for drug studies, and as a contract development and manufacturing company for the pharmaceutical industry. Headquartered in Neu-Ulm, Germany, Nuvisan operates seven sites in Germany and France.
Background: ALS instructed Greenberg Traurig Germany for the first time. The Greenberg Traurig team prevailed in a pitch against other law firms. It provided comprehensive advice on the transaction, including on the legal due diligence, the purchase agreement, a shareholders' agreement, and the registration under foreign trade law.
About Greenberg Traurig: Greenberg Traurig, LLP (GT), has approximately 2200 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. The firm is net carbon neutral with respect to its office energy usage and Mansfield Rule 3.0 Certified. Web: www.gtlaw.com
ALS is a global provider of laboratory testing, inspection and certification services based in Brisbane, Australia. The company operates testing centers worldwide and provides services particularly to the pharmaceutical and healthcare industries.
Nuvisan operates internationally both as an independent contract research organization, for example for drug studies, and as a contract development and manufacturing company for the pharmaceutical industry. Headquartered in Neu-Ulm, Germany, Nuvisan operates seven sites in Germany and France.
Background: ALS instructed Greenberg Traurig Germany for the first time. The Greenberg Traurig team prevailed in a pitch against other law firms. It provided comprehensive advice on the transaction, including on the legal due diligence, the purchase agreement, a shareholders' agreement, and the registration under foreign trade law.